UBS Group’s Regentis Biomaterials RGNT Stock Holding History

UBS Group’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53K	Buy	434 +100	+30%	+$285	﹤0.01%	9527
2026 Q1	$1.02K	Buy	+334	New	+$1.6K	﹤0.01%	9642

Other funds holding RGNT

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's RGNT Position: Q2 2026 in Review

UBS Group increased its Regentis Biomaterials (RGNT) stake by 30% in Q2 2026, buying an estimated $285 and bringing the position to 434 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #9527.

UBS Group first reported a position in RGNT in Q1 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold RGNT as of Q2 2026.

UBS Group held 434 shares of Regentis Biomaterials worth $1.53K as of Q2 2026.
UBS Group bought 100 Regentis Biomaterials shares in Q2 2026, an estimated $285.
Regentis Biomaterials made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9527 holding.
UBS Group first reported a position in Regentis Biomaterials in Q1 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.